Dianthus Therapeutics, Inc. (DNTH) saw its share price increase by 5.6% to close at $83.92 following a strong trading session. This surge is part of a broader 43.8% gain over the past month, driven by investor optimism regarding its ongoing clinical trials, particularly the late-stage CAPTIVATE study evaluating claseprubart for chronic inflammatory demyelinating polyneuropathy (CIDP). The FDA’s approval of key clinical development changes further buoyed investor confidence.
The company is expected to report a quarterly loss of $1.17 per share, reflecting a 42.7% year-over-year decline, with projected revenues of $0.55 million, down 53% from the previous year. Across the past 30 days, the consensus EPS estimate has been revised 27.6% lower, suggesting potential challenges ahead for share appreciation. Dianthus currently holds a Zacks Rank of #3 (Hold).
